-
Uncategorized2 months agoSTAT+: Baby KJ scientists hit road bump in quest to scale custom gene editor
The scientists behind treating Baby KJ say they’ve hit a stumbling block in their efforts to create more custom gene editing treatments for children with rare...
-
Uncategorized2 months ago
Iterum initiates wind-down after failure to offload antibiotic with sluggish sales
Irish antibiotic specialist Iterum Therapeutics has started winding down its operations, citing limited cash amid the expensive commercialization of its only approved product, Orlynvah.
-
Uncategorized2 months agoSTAT+: Pharmalittle: We’re reading about pharma delaying launches in Europe, Lilly and Biogen deals, and more
Rise and shine, everyone, another busy day is on the way. And it is getting off to a good start here on the Pharmalot campus, where...
-
Uncategorized2 months ago
Avo raises $10M to help doctors with workflow
Avo, a startup that uses patients’ health records to help doctors handle paperwork and make decisions, has raised $10 million, Endpoints News learned exclusively. When a...
-
Uncategorized2 months agoA new survey examines mental health outcomes of gender euphoria
Good morning. Reporters get countless email pitches every day. Just yesterday, I got one that mentioned Hannah Montana in the subject line. But the pitch that...
-
Uncategorized2 months ago
Merck joins forces with Infinimmune to find therapeutic antibodies
Merck is tasking a 10-person biotech to hunt for new human antibody candidates. The drug giant will ship up to $838 million to the startup, called...
-
Uncategorized2 months agoMerck strikes deal with antibody discovery startup
In an R&D collaboration worth as much as $838 million, Merck will lean on Infinimmune to discover immune cell-directed antibodies for multiple targets. Read More
-
Uncategorized2 months agoDDW Highlights: 31 March 2026
The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates the key stories of the previous week to keep...
-
Uncategorized2 months ago
Biogen to buy Apellis for $5.6B
Biogen has made a $5.6 billion deal to acquire Apellis Pharmaceuticals, the companies announced Tuesday. The deal will allow Biogen to get hold of the kidney...
-
Uncategorized2 months ago
Eli Lilly to buy Centessa for $6.3B to get sleep disorder drug
Eli Lilly to buy Centessa for $6.3B to get sleep disorder drug
STAT+: Updated: Tracking RFK Jr.’s promises to remake health in America
An obesity drug deep-dive, and peptides move mainstream
